Revenue up 49% but EBITDA loss widened 68% and NPAT loss doubled

What changed

Revenue rose 49.0% to NZ$3.6m from NZ$2.4m, with gross margin widening to 39.5% from 35.8% as cost of sales grew slower than sales. Despite that, the operating EBITDA loss deepened to NZ$3.1m from NZ$1.8m (-68.5%), and the statutory loss after tax widened to NZ$5.8m from NZ$2.8m (-109.3%). Restructuring-related items account for roughly NZ$0.8m of the gap between the NZ$5.0m operating loss before restructure and PBT of NZ$5.8m. Operating cash outflow was essentially unchanged at NZ$4.6m. The balance sheet contracted materially: total assets fell 26.5% to NZ$33.9m, equity fell 32.4% to NZ$19.0m, while gross borrowings eased 6.2% to NZ$12.3m and cash was flat at NZ$2.3m. Segment mix shifted further toward Honey, which rose to 69.7% of external revenue from 51.8%.

What matters

• The loss widened despite the revenue recovery. EBITDA loss deterioration of NZ$1.3m on a NZ$1.2m revenue lift indicates costs grew faster than the incremental gross profit, so operating leverage is still negative at this scale.
• Honey is doing the heavy lifting but remains structurally loss-making. The dominant segment (NZ$2.5m revenue, 69.7% share) is running at an implied EBITDA margin of roughly -42.2%, worse than -23.7% a year ago. Sale of goods fell to NZ$0.8m from NZ$1.0m and its EBITDA margin deteriorated to roughly -153.8%.
• Inventory is the single largest balance-sheet item. Inventories rose 10.8% to NZ$15.6m and represent about 46% of total assets, against NZ$3.6m of half-year revenue. Management previously flagged significant honey stocks; that overhang has not meaningfully cleared.
• Customer concentration is disclosed. Management again cites the performance of its largest customer in the Chinese market as a driver of sales volatility.

Expectations

No numeric targets or forward-work balance were disclosed. Management commentary is qualitative: the group states it has sufficient funding for operations while focusing on sales growth through FY23. Annualising HY23 revenue implies about NZ$7.2m full-year, roughly 87% of FY22's NZ$8.3m, but FY22 was strongly second-half weighted (H1 was only 29.2% of FY revenue, 32.3% of FY EBITDA and 14.2% of FY NPAT). If a similar H2 skew repeats, FY23 revenue could exceed the annualised run-rate, but the release provides no pipeline or order-book metric to anchor that.

Quality of result

Low quality. PBT and NPAT are identical because tax was nil in both periods, so there is no below-the-line distortion to unwind — the wider loss is an operating result. Cash conversion deteriorated in relative terms: OCF/EBITDA moved to 150.9% from 253.4%, meaning each dollar of EBITDA loss is producing less incremental cash drag, but absolute operating cash burn of NZ$4.6m is broadly unchanged against a larger EBITDA loss, which is partly explained by working-capital movements (receivables days fell sharply to 86 from 145, offsetting the NZ$1.5m build in inventory). Capex was minimal at NZ$15k versus NZ$174k prior, flattering pre-lease free cash flow to -NZ$4.7m (vs -NZ$4.8m); that is a timing/investment choice rather than underlying improvement. The 49% revenue growth itself is against a low base and comes with the caveat that HY22 revenue of NZ$2.4m was a step down versus HY22's "revenue before marketing services provided by a customer" gross figure.

Unresolved

• What is the achievable selling price and sell-through rate on the NZ$15.6m honey inventory, and is there any impairment risk if demand remains soft?
• What proportion of revenue is attributable to the largest Chinese customer, and has any re-contracting occurred?
• What is the cash runway? With NZ$2.3m of cash, NZ$4.6m of half-year operating outflow, and NZ$12.3m of gross borrowings (of which NZ$0.5m is current), funding adequacy depends on facility headroom and covenant terms that the release does not quantify.
• What restructuring costs remain to be taken, and what is the targeted steady-state operating cost base?
• This briefing cannot assess liquidity runway, covenant headroom, or the realisability of the honey inventory without disclosure of facility terms, forward orders, and stock-level impairment testing.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.